Flow Cytometry Solution for In Vivo CAR-T Delivery: LNP & Viral Vector Characterization

Q: How does flow cytometry evaluate the functionality of CAR-T cells?

Common functional assessments include: (1) In vitro cytotoxicity assays, where CAR-T cells are co-cultured with fluorescently labeled target cells, and the remaining target cells are quantified by flow cytometry to calculate killing efficiency; (2) Degranulation assays measuring surface CD107a expression; and (3) Intracellular cytokine staining (ICS) to detect effector molecules such as IFN-γ, TNF-α, and IL-2.

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Developing effective in vivo CAR-T therapies faces significant challenges, including inconsistent LNP or viral vector quality, off-target delivery, and inefficient transduction characterization. Our flow cytometry solutions for in vivo CAR-T delivery, specifically designed for LNP and viral vector characterization, directly address these bottlenecks. We provide a comprehensive panel of assays that quantify vector integrity, titers, host cell engagement, and CAR expression with high resolution. Our solutions offer high sensitivity, multiparametric analysis, and rapid turnaround, enabling you to accelerate lead candidate selection, de-risk delivery efficiency, and ensure reproducible therapeutic outcomes.

Introduction

CAR-T therapy represents a groundbreaking personalized immunotherapy that genetically modifies a patient's own T cells to recognize and eliminate tumor cells in a major histocompatibility complex (MHC)-independent manner. LNPs and viral vectors, including lentiviral and retroviral systems, serve as two primary delivery platforms: viral vectors enable stable genomic integration of the CAR transgene through efficient transduction, whereas LNPs offer a non-viral, transient, and scalable alternative with reduced immunogenicity and insertional mutagenesis risk. The application of LNPs and viral vectors for CAR-T delivery is pivotal, as it not only ensures precise and durable CAR expression in T cells but also addresses key challenges in manufacturing complexity, safety, and potential in vivo T cell targeting, thereby broadening the therapeutic accessibility and efficacy of CAR-T therapy.

Fig.1 In vivo generation of CAR-T cells via nano-delivery platforms. (OA Literature) Fig.1 Employing nano-delivery systems for the in vivo production of CAR-T cells.¹

Our Service

Our flow cytometry solutions enable precise in vivo characterization of LNP and viral vectors for CAR-T delivery. We assess biodistribution, transduction efficiency, and CAR expression kinetics, supporting pharmacodynamics and safety. With high sensitivity and multiparametric analysis, these assays empower researchers to optimize delivery systems and accelerate development of cell therapies.

What We Can Offer

Following in vivo administration of the delivery system, be it LNP or viral vector, flow cytometry remains the benchmark technique for monitoring the resulting CAR-T cells. Such tracking is critical for evaluating pharmacodynamic responses and ensuring safety profiles.

Featured services of flow cytometry solutions for in vivo CAR-T delivery: LNP & viral vector characterization at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Preclinical Biological Samples: Whole blood, spleen, bone marrow, tumor tissue, or lymph nodes to evaluate the in vivo targeting efficiency of LNP/viral vectors.
Clinical Biological Samples: Patient peripheral blood, core needle biopsy tissues, or bone marrow aspirates to validate clinical efficacy and monitor safety profiles.

Key Steps:

Workflow of flow cytometry solutions for in vivo CAR-T delivery: LNP & viral vector characterization at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: We generate absolute CAR-T cell counts or percentage curves over time, including expansion peak, plateau, and contraction phases, to evaluate the in vivo transfection efficiency of LNP or viral vectors.

Key Advantages

Direct Comparison of Delivery Platforms: This solution enables a direct, quantitative comparison of gene delivery efficiency between LNP and viral vector platforms.
Quantitative Assessment of Optimization Strategies: It allows for the precise quantification of how different targeting molecule ratios, such as CD3/CD28 antibody combinations, directly impact both the percentage and mean fluorescence intensity of CAR-positive cells, facilitating the selection of optimal formulations.
Validation of In vivo Transfection: This approach provides critical proof-of-concept for in vivo CAR-T generation by directly demonstrating successful CAR protein expression on T cells harvested from organs like the spleen after intravenous injection of targeted LNPs.
Comprehensive Multi-Parameter Analysis: The core advantage lies in its ability to perform high-dimensional, high solution analysis, simultaneously profiling up to dozens of characteristics such as CAR expression, effector function, and differentiation phenotype for a holistic assessment.

FAQ

Q1: How can flow cytometry distinguish between CAR-T cells generated by LNP versus viral vector transduction?

A1: LNP-mRNA transduction leads to transient CAR expression, typically peaking within 24–72 hours and declining by day 5. In contrast, lentiviral vectors produce sustained CAR expression through genomic integration, lasting months to years. Thus, the timing of flow cytometric analysis should align with the experimental goal: assess transfection efficiency by measuring CAR positivity at 24-48 hours post-transduction, while evaluate persistence through serial monitoring at time points such as day 7, 14, and 28.

Q2: How does flow cytometry evaluate the functionality of CAR-T cells?

A2: Common functional assessments include: (1) In vitro cytotoxicity assays, where CAR-T cells are co-cultured with fluorescently labeled target cells, and the remaining target cells are quantified by flow cytometry to calculate killing efficiency; (2) Degranulation assays measuring surface CD107a expression; and (3) Intracellular cytokine staining (ICS) to detect effector molecules such as IFN-γ, TNF-α, and IL-2.

Why Choose Us?

We deliver end-to-end flow cytometry solutions for precise in vivo CAR-T delivery, validating LNP and viral vector integrity, titer, and transfection efficiency. Count on high-resolution immunophenotyping, rigorous quality control, and streamlined workflows to accelerate your cell therapy development with confidence and reproducibility.

Customer Reviews

"We used their flow cytometry assays to characterize both LNP and AAV vectors side-by-side. The consistency and reproducibility were outstanding, allowing seamless transition from in vitro optimization to in vivo validation." Dr. Sophia K. Lee.

"The ability to simultaneously assess vector quality and CAR-T cell functionality in vivo was a game-changer. This solution reduced our QC turnaround time by 40% without compromising data integrity." Dr. Michael R. Patel.

"Highly recommended for labs focusing on in vivo CAR-T delivery. The LNP characterization panel was thorough, and the viral vector titration protocols were clearly validated for low-abundance samples." Dr. Anna V. Richter.

How to contact us?

Ready to accelerate your in vivo CAR-T program with robust LNP and viral vector characterization? Reach out today to discuss customized flow cytometry panels, technical validations, or bulk pricing. Our application scientists are available to answer your questions and support your preclinical to clinical journey.

Reference

Xin, Tianqing et al. "In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy." Frontiers in oncology vol. 12 809754. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fonc.2022.809754.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.